ABOUT US
R&D
AGORA
PR
RECRUITMENT
CONTACT
Moonkyung Choe, Ph.D., CEO of 3H Bio Co., Ltd., Korea.
She received her Ph.D. degree from the College of Science and Convergence Technology, Hanyang University in Korea, and was trained as a researcher in Postech and Gachon University, Korea.
Hyung-Ji Kim, M.D., Ph.D., is Co-CEO of 3H Bio Co., Ltd., Korea, and concurrently works as an assistant professor at the Department of Neurology, Eulji University School of Medicine.
He received his Ph.D. degree from the College of Medicine, University of Ulsan, and has trained as a dementia specialist at Asan Medical Center, Seoul, Korea.
Hyo Joon Kim, Ph.D., COO of 3H Bio Co., Ltd., Korea, is an Emeritus Professor at the Division of
Molecular and Life Science, Hanyang University.
He received his Ph.D. degree from the College of Pharmacy, Osaka University in Japan, and was trained as a Post Doc in the Center for Cancer Research at MIT, USA.
His scientific research on obesity immunotherapeutics has been supported by successive
grants from the Ministry of Sciences and Technology,
the Ministry of Knowledge and Economy,
and the Ministry of Education, Science and Technology of Korea.
Mr. Choi, Jae Kyoung is the co-founder of 3H Bio working as CFO.
He has been working as company builder and venture capital since 1997.
He has various experience in company building and
venture capital including from co-founding to being listed on stock market.
He was the co-founder of I-Venture Capital as CEO and managing director of investment in Actnerlab.
He got MBA degree from the University of Sydney and the University of Texas at Austin.
Hyun Ryoung Kim, Ph.D., is the CTO of 3H Bio Co., Ltd., Korea.
She graduated from the University of Paris XI with a Ph.D. in pharmacy.
She worked then at the Samsung Advanced Institute of Technology as a project leader in the drug formulation research group, and at Daewoong Pharmaceuticals as a team leader in the New Product R&D Center.
Subsequently, she worked as CTO in a biotech-based company.
She has 17 years of professional experience in CMC.
Bert Binas, Ph. D., CSO of 3H Bio Co., Ltd., Korea.
He has a professional background in lipid metabolism and stem cell biology.
He received his doctorate in Cellular Biochemistry at the Central Institute for Molecular Biology (Germany), and postdoctoral training at the Roslin Institute (U. K.) and the Max Delbrueck Center for Molecular Medicine (Germany).
He was then an Associate Professor at Texas A&M University (USA) and a - now retired - Full Professor at Hanyang University (Korea).
Min Jae Kim, Ph.D., CDO of 3H Bio Co., Ltd., Korea.
He received his Ph.D. degree from the College of Science and Convergence Technology,
Hanyang University in Korea, and was trained as Post Doc in the same place.
Munsik Seol has served as Auditor in 3H Bio Co., Ltd., since 2021.
He graduated Seoul National University with a bachelor's degree in Economics.
He had worked in finance and budget for more than 30 years in the Ministry of Finance, Budget Administration, Presidential Office, Ministry of Economy and Finance in Korea government.
He had worked as Vice Governor of economic affairs in Chungcheongbuk-Do Province from 2012 to 2017.
He also served as chairman of Board of Chungcheong University from 2021 to February 2023.
On the one hand, he also serves as an advisor to global e-commerce company Alibaba.com Singapore E-Commerce Private Limited.
Henry M. Kaiser, Psy.D., MBA, is an Advisor for 3H Bio Co., Ltd.
He got an MBA degree from the Stanford University Graduate School of Business, and a Psy.D.
degree from Meridian University. He is Chairman Emeritus of Thomsen’s Inc.
He has served in numerous leadership roles on Portfolio Company Boards and community and arts organizations.
He previously served as President and sat on the Board of Directors of Kaiser Foundation International’s global health care consulting activity,
as a Director of the Kaiser Foundation Hospitals & Health Plan, and as a Trustee of Kaiser Family Foundation.
David Arthur Berry, M.D., Ph.D., is an Advisor for 3H Bio Co., Ltd.
He got an M.D. degree from Harvard Medical School, a Ph.D. degree from the Massachusetts Institute of Technology.
He has co-founded more than 25 companies, including Seres Therapeutics, Indigo Agriculture, and Axcella Health.
He previously served as Founder and CEO of Valo Health, as general partner at Flagship Pioneering, and is now running with his brother Bedford Bridge, a $300 million health tech and longevity VC firm.
He is also an early founding developer of Moderna.
Arthur Paul Becker is an Advisor for 3H Bio Co., Ltd.
He is the current CEO of Oncopep, a cancer vaccine company.
He is a Venture Partner with CoBro Ventures and is on the Boards of NextRNA, AI Proteins, and OncoPep.
He is also a Managing Member of Madison Technology, LLC, an investment firm.
He was formerly the Chairman & CEO of Zinio, LLC, the world’s largest digital newsstand.
Ryan Chin is an Advisor for 3H Bio Co., Ltd.
He is CEO & Managing General Partner at Black Kestral Group, a Private Investment Office & Consultancy (Singapore family office).
Black Kestral Group is a member of Xen Capital Pte. Ltd.
Chong Sam Chi is an Advisor for 3H Bio Co., Ltd.
He is the CEO of Trident Global Holdings & Trident Investment Holdings.
He served as Vice president of JP Morgan from 1998 to 2002.